Joshua Fitch, Editor

As children get set to head into the sun, grass, and water, now is the perfect time to remind patients and parents about best practices, treatments, and preventive measures.

In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.

Investigators state public health strategies should prioritize early detection of mental health needs and equitable access to it, as some Medicaid-enrolled children are not receiving mental health services following a firearm injury.

An increase in outpatient visits that included an anxiety diagnosis was also met with a decrease in treatment visits, while there was no significant change in the overall use of medications in all time periods.

Semaglutide (Wegovy; Novo Nordisk) for obesity in adolescents, along with 2 other approved products containing semaglutide, are currently on the FDA’s drug shortages list, prompting the agency to warn patients and providers about drug compounding.

The at-home test correctly identified 98.7% of negative and 92.9% of positive samples for individuals with signs and symptoms of upper respiratory infection, according to a study reviewed by the FDA.

Compared to 2017, new HIV infections overall were 12% lower in 2021, falling from approximately 36,500 to 32,100 infections, respectively, according to the CDC.

Risk detection practices and targeted interventions promoting adaptive developmental trajectories for at-risk children can be successful by identifying the earliest antecedents of persisting emotional and behavioral dysregulation.

Timing of administration of epinephrine was not associated with survival to discharge for pediatric out-of-hospital cardiac arrest patients, but overall use of epinephrine was.

In this Contemporary Pediatrics® interview, Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California, details the rise in pediatric mental health concerns, emergency department visits, and the potentially concerning aspects of social media among youth.

Devan Jaganath, MD, MPH, pediatric infectious disease physician, University of California San Francisco Benioff Children's Hospitals, explains how Hyfe AI and other artificial intelligence algorithms can detect and monitor coughing, potentially playing a role in treating RSV patients.

Family history, seasonal change, swimming, and several other factors can contribute to dry skin, according to the Society for Pediatric Dermatology.

Over 50% of parents said they have used pre-owned child health and safety equipment. Whether it comes from family or a stranger, from cribs to car seats, all equipment should be inspected and researched before allowing a child to use it according to a C.S. Mott Children’s Hospital National Poll on Children’s Health.

The Beta Bionics iLet ACE Pump and the iLet Dosing Decision software, matched with a compatible FDA-cleared integrated continuous glucose monitor, use an algorithm to determine and command insulin delivery to users.

The US Department of Education, US Department of Health and Human Services, and the Biden-Harris Administration look to increase access to school-based health services, including mental health services, amid the national crisis. 

Up to 95% of youth aged 13 to 17 years reported using a social media platform and more than a third said they use social media, “almost constantly,” according to a new advisory from the Surgeon General.

Finafta Anesthetic/Analgesic Liquid, containing 60% ethyl alcohol and 5% benzocaine has been found in the G-Supress DX Pediatric Cough Drops packaging, according to the FDA.

The newly FDA-approved prescription product delivers nalmefene to the nasal cavity to reverse the effects of opioid overdose.

Patients using adalimumab-adbm for chronic inflammatory disease treatment such as juvenile idiopathic arthritis (JIA), Crohn’s disease, and others, will have an autoinjector option beginning July 1, 2023, according to Boehringer Ingelheim.

Following the FDA approval of beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older, Bernard A. Cohen, MD, discusses its safety and efficacy and how it can change the treatment landscape for DEB.

The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.

The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.

This formulation of ibuprofen is the only non-opioid product approved to treat pain in infants that is delivered through injection, according to Cumberland Pharmaceuticals.

Thomas R. Young, MD, discusses how important early screening is in children and adolescents with regard to mental health. He believes a reduction in stigma associated with mental health is occurring and that primary care professionals are encouraging youth to discuss what might be bothering them.

The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.

A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.

Nirsevimab’s efficacy against infant hospitalizations due to respiratory syncytial virus was reinforced after a phase 3b clinical trial, demonstrating an 83% reduction in infant hospitalizations.

Contemporary Pediatrics® Editorial Advisory Board member Andrew Schuman, MD, clinical assistant professor of pediatrics, Geisel School of Medicine, Dartmouth, shares some questions pediatricians can expect from parents as the federal COVID-19 public health emergency (PHE) expires.

Since May is Mental Health Awareness Month, the American Academy of Pediatrics is offering several tips to help a suspected self-harming child.

Tina Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief, Contemporary Pediatrics®, discusses how the cost burden of the federal COVID-19 public health emergency (PHE) expiration on May 11, 2023, can impact testing and vaccination rates among children.